🩺 Biomarker Companion Diagnostic

Tissue Biopsy and Liquid Biopsy — Capturing the Tumor's Molecular Portrait

Before any treatment decision, oncologists need to know the molecular identity of a patient's cancer. Two complementary sampling strategies answer different questions: tissue biopsy reveals the spatial architecture and protein expression of the primary tumor; liquid biopsy from blood captures circulating tumor DNA that represents the whole tumor — including metastases that are invisible to biopsy.

• 85–92%: Tissue biopsy accuracy (concordance with excision)
• 0.01% VAF: ctDNA detection limit (ddPCR sensitivity)
• 5–7 days: Biopsy-to-result time (standard FFPE IHC)
• 3–5 days: Liquid biopsy time (cfDNA NGS turnaround)

FFPE tissue preparation — why formalin fixation matters

Formalin-fixed paraffin-embedded (FFPE) processing is the century-old backbone of clinical pathology. But its chemistry matters for molecular testing:

Formalin fixation chemistry: • Formaldehyde (HCHO) forms methylene bridges between amino groups in proteins • These crosslinks preserve tissue architecture by preventing autolysis • Side effect: DNA crosslinks with proteins, making it difficult to extract high-quality nucleic acids • RNA is particularly vulnerable: mRNA degrades within hours; IHC and ISH work but RNA-seq is challenging from FFPE

FFPE blocks for IHC: • 4 µm sections cut from paraffin block on microtome • Sections mounted on positively charged slides (prevent detachment) • Dewaxing: heat 60°C, then xylene to dissolve paraffin • Rehydration: ethanol gradient → water • Antigen retrieval: heat-induced epitope retrieval (HIER) — boiling in citrate buffer pH 6 breaks formaldehyde crosslinks and restores protein epitope conformation

Contemporary challenges: • Intratumor heterogeneity: a single biopsy core samples < 0.01% of a large tumor volume • Different regions of the same tumor may have different molecular profiles • This is why liquid biopsy is complementary: ctDNA represents average of all tumor clones, including distant metastases • Baseline biopsy at diagnosis, re-biopsy at progression: acquired resistance mechanisms differ from primary tumor

Immunohistochemistry — Seeing Protein Expression in Every Cell

Immunohistochemistry is a molecular microscopy technique that uses antibodies as precision targeting agents to dye specific proteins visible under a light microscope. By conjugating antibodies to enzymes that produce colored precipitates, pathologists can directly see which cells express a biomarker, how intensely, and in what cellular compartment — information invisible to molecular assays that homogenize tissue.

• 1:100–1:1000: Antibody concentration (typical primary antibody dilution)
• 450 nm: DAB wavelength (brown chromogen absorbance peak)
• >30%: HER2 3+ threshold (cells with strong membrane stain)
• 85–92%: Inter-lab concordance (HER2 IHC reproducibility)

IHC detection systems — antibody, secondary, enzyme, chromogen cascade

The IHC signal amplification chain transforms a single protein binding event into a visible colored deposit:

Direct IHC (historical, rare): • Primary antibody directly conjugated to enzyme (HRP or AP) • Simple, fast; poor sensitivity — only 1 signal molecule per target

Indirect IHC (standard): 1. Primary antibody (unconjugated, high-affinity anti-HER2) binds HER2 protein in tissue 2. Secondary antibody (anti-IgG, conjugated to HRP polymer) binds primary Polymer-HRP systems (EnVision, OptiView): 40–100 HRP molecules per secondary 3. DAB chromogen added: HRP catalyzes H2O2 oxidation of diaminobenzidine (DAB) into insoluble brown polymer Precipitates exactly where HRP is located = where the target protein is 4. Hematoxylin counterstain: binds nucleic acids (DNA), staining nuclei blue-purple Result: brown HER2 protein on blue/purple nuclear background

Critical controls every IHC run: • Positive control: cell line known to express target at 3+ • Negative control: same antibody concentration, but replaced with non-immune IgG (isotype control) If negative control shows brown staining = non-specific background • External quality assurance: College of American Pathologists (CAP) and NordiQC send proficiency testing samples to >2500 labs globally

HER2 IHC scoring per ASCO/CAP 2018 guidelines: • 0: no staining or < 10% cells with faint/incomplete membrane • 1+: > 10% cells with faint/incomplete basolateral or lateral membrane • 2+: > 10% cells with weak-to-moderate, complete or incomplete membrane (equivocal — requires FISH confirmation) • 3+: > 10% cells with strong, complete membrane staining — diagnostic for HER2 positivity

New 2023 revision — HER2-low category: • IHC 1+ or IHC 2+/FISH-negative now classified as "HER2-low" • Trastuzumab deruxtecan (T-DXd) is effective in HER2-low patients — this reclassification doubled the eligible population from 15% to 50–55% of breast cancer patients

Digital Pathology and AI — Seeing the Slide Through Machine Eyes

A whole-slide image at 40× magnification contains 4 billion pixels and perhaps 500,000 individual cancer cells. Human pathologists reading 50 slides per day for a decade acquire unparalleled pattern recognition — but they are slow, expensive, and show inter-observer variability on borderline cases. AI algorithms trained on millions of annotated cells can score every cell on a slide in 3 seconds, with better reproducibility than humans on IHC assays.

• 800 MB: Whole-slide image size (40× scan, 0.25 µm/px)
• 3–8 sec: AI inference time (per whole WSI, GPU-accelerated)
• 96%: PathAI HER2 concordance (vs. expert pathologist consensus)
• 38%: Borderline (2+) reclassification (AI changes initial read in 2+ cases)

Computer vision in pathology — from pixel to diagnosis

Digital pathology AI pipelines involve multiple models working in sequence:

1. Tissue detection model: • Identifies tissue regions vs. background (air/glass) • Low-resolution inference (4×) to create tissue mask • Model: typically simple U-Net or even OpenCV thresholding

2. Tumor detection model: • Classifies patches (256×256 px) as tumor, stroma, immune infiltrate, necrosis • Attention-MIL (multiple instance learning): trained on slide-level labels (cancer or not) without pixel-level annotation • Foundation models (PathFoundation, UNI, CONCH): 100M–1B parameter ViT trained on 50–500M image patches

3. Cell segmentation and classification: • Instance segmentation: Mask R-CNN or StarDist identifies individual cell boundaries • Classifies each cell: carcinoma, lymphocyte, fibroblast, endothelial • For HER2: quantifies membrane staining intensity per carcinoma cell using RGB channel analysis

4. HER2 H-Score computation: • For each tumor cell: extract 50 pixel average along detected cell membrane boundary • Map brown-purple ratio in DAB Hematoxylin color space (via Macenko stain deconvolution matrix) • Classify intensity: 0, 1+, 2+, or 3+ per cell • H-Score = Σ(%3+ cells × 3) + Σ(%2+ cells × 2) + Σ(%1+ cells × 1), range 0–300

FDA-cleared AI CDx algorithms: • PathAI/Lilly HER2 companion diagnostic: clearance 2023 • Paige EGFR/ALK for lung: clearance 2022 • Proscia Concentriq: FDA-cleared primary diagnosis viewer

Regulatory pathway: FDA De Novo or 510(k) pathway for software as a medical device (SaMD); requires validation on prospective locked dataset with locked algorithm

Circulating Tumor DNA — Reading the Tumor's Genome from a Blood Draw

Cancer cells shed fragments of their DNA into the bloodstream as they die. This circulating tumor DNA (ctDNA) represents the entire tumor genome — including all subclones, all metastatic lesions, and acquired resistance mutations that emerged after treatment. With digital PCR and next-generation sequencing, we can detect one mutant DNA molecule among 10,000 wild-type molecules, using only 2 milliliters of plasma.

• 167 bp: cfDNA fragment size (mono-nucleosomal internucleosomal)
• 0.01–50%: ctDNA fraction in blood (depends on tumor stage and type)
• ±5%: ddPCR precision (quantifies copy number changes)
• 74: Guardian-360 CDx genes (FDA-cleared pan-solid tumor NGS)

Cell-free DNA biology and liquid biopsy assay design

Cell-free DNA (cfDNA) biology: • All nucleated cells shed DNA into plasma 24 hours a day via apoptosis and necrosis • Apoptotic cfDNA: 167 bp fragments corresponding to mono-nucleosome unit (146 bp DNA wrapped around histone octamer + 21 bp linker) • Cancer cells suffer higher turnover rates and shed more DNA: ctDNA may be 0.01% (early stage I) to 50% (late metastatic) of total cfDNA • ctDNA half-life in plasma: ~1–2 hours (cleared by kidneys and liver); real-time pharmacodynamic marker

cfDNA isolation: • Streck BCT (blood collection tube): formalin preserves cell integrity, preventing genomic DNA contamination • Benzonase-free protocol: spin 1600×g 10 min then 3000×g 10 min to remove cells and platelets • Silica-membrane spin column or size-exclusion bead-based extraction • Yield: 2–30 ng cfDNA per 4 mL plasma

Digital droplet PCR (ddPCR) for known mutations: • Sample partitioned into 20,000 nano-droplets; each contains 0 or 1 template molecules • Droplets amplified to endpoint (40 PCR cycles) • FAM-labeled probe: wild-type → high fluorescence; VIC-labeled probe: mutant → intermediate fluorescence • Poisson statistics: ratio of mutant:total droplets = mutant allele fraction • Dynamic range: 0.01%–100% VAF • Applications: KRAS G12C monitoring during osimertinib, ESR1 D538G in aromatase inhibitor-resistant ER+ breast cancer

Next-generation sequencing panel (ctDNA-NGS): • Hybrid capture (IDT xGen) enriches target regions • 500–1000× sequencing depth — deep enough to detect 0.1% VAF variants • Unique Molecular Identifiers (UMI): barcodes ligated to each cfDNA fragment before PCR PCR duplicates sharing identical UMI removed; sequencing errors (1 in 1000 bases) distinguished from true mutations (appear in all UMI families) • Foundation Medicine F1 CDx: FDA-approved pan-cancer companion diagnostic covering 324 genes • FoundationOne Liquid CDx: plasma-based, 324-gene, FDA-approved for multiple tumor types and companion drugs

Multi-Biomarker Integration — Sorting Patients to the Right Treatment

Modern precision oncology does not pick a treatment first and then find patients who respond. It measures first — comprehensively, at the DNA, RNA, and protein level — and then assigns each patient to the therapy that targets their tumor's specific vulnerability. The result: dramatically higher response rates, less toxicity, and a transformation of cancer from a tissue-of-origin diagnosis to a molecular one.

• 60–70%: HER2 3+ response rate (trastuzumab + pertuzumab)
• 46%: PD-L1 TPS >50% ORR (pembrolizumab monotherapy)
• 56%: BRCA1/2 olaparib ORR (vs. 13% chemo (OlympiAD))
• 32%: Precision Rx allocation (of unselected patients)

The precision oncology decision tree — biomarker → targeted therapy

Multi-biomarker integration algorithm:

Step 1: Tumor mutational burden (TMB) • Calculate mutations per megabase from NGS panel • TMB-High (≥10 mut/Mb): FDA-approved pembrolizumab regardless of tumor type — first pan-tumor biomarker approval (2020) • TMB-Low: proceed to other biomarkers

Step 2: Microsatellite instability (MSI) / mismatch repair (MMR) • MSI-High or dMMR: FDA-approved pembrolizumab (any solid tumor, 2017 — first tissue-agnostic approval in oncology history) • Detected by fragment length analysis or IHC for MLH1, MSH2, MSH6, PMS2

Step 3: HER2 status • IHC 3+ or FISH amplification ratio ≥2.0: trastuzumab + pertuzumab + chemotherapy • IHC 1+ or IHC 2+/FISH-negative (HER2-low): trastuzumab deruxtecan (T-DXd) — 2022 approval

Step 4: PD-L1 (programmed death-ligand 1) expression • 22C3 pharmDx (Dako): approved CDx for pembrolizumab in lung,gastric,cervical,esophageal cancers • TPS (tumor proportion score): percentage of tumor cells with membrane staining • CPS (combined positive score): includes immune cells; used for gastric/cervical

Step 5: Actionable mutations • EGFR exon 19 del, exon 21 L858R: osimertinib (FLAURA), erlotinib • ALK/ROS1 fusion: alectinib (ALEX), lorlatinib • KRAS G12C: sotorasib (CodeBreaK100), adagrasib (KRYSTAL-1) • BRCA1/2 germline/somatic: olaparib, niraparib, rucaparib (PARP inhibitors) • NTRK1/2/3 fusion: larotrectinib, entrectinib (pan-tumor) • RET fusion: selpercatinib, pralsetinib • MET exon 14 skip: capmatinib, tepotinib

Failed precision oncology (lessons): • EGFR-mutant NSCLC responds to gefitinib → initially tried in all NSCLC without biomarker selection → failed in unselected trials → biomarker-positive subgroup analysis rescued it → PDX-based co-clinical trial design now standard

The 2023 CROWN trial showed lorlatinib (ALK inhibitor) produced 60% 5-year progression-free survival in ALK-positive NSCLC patients — better than any chemotherapy ever achieved in lung cancer. The companion diagnostic ALK IHC D5F3 CDx test was developed concurrently with the drug, enabling a 1:1 patient-drug match that makes the 60% survival rate possible. This is precision oncology working as intended.

Regulatory framework — companion diagnostic co-development

FDA requires companion diagnostic approval in parallel with the drug when the drug's labeling claims efficacy only in biomarker-defined population:

Co-development timeline: • Phase 1–2: exploratory biomarker analysis identifies potential CDx candidate • Phase 2b: CDx assay locked and analytically validated (ISO 13485 quality system) • Phase 3: prospective collection of paired tissue/blood specimens; CDx used to allocate treatment • Submission: drug NDA/BLA + CDx PMA submitted simultaneously • FDA review: drug and CDx reviewed by different CDER/CDRH divisions but coordinated

CDx analytical validation requirements: • Precision: repeatability (same lab same day) + reproducibility (different labs) • Accuracy: concordance with reference method (clinical truth derived from clinical outcomes) • Sensitivity/specificity vs. reference standard (RNA-ISH, NGS, or adjudicated clinical dataset) • Lot-to-lot variability: 3 independent lots tested • Cut-point validation: pre-specified in Statistical Analysis Plan before any efficacy analysis

Global regulatory differences: • FDA: CDx required for on-label use of companion drug; off-label use possible with LDT • EMA: IVD Regulation (IVDR) 2022 — stricter classification, requires Notified Body certification • Japan PMDA: parallel CDx review program similar to FDA • China NMPA: domestic CDx manufacturing preference through preferential review

Laboratory developed tests (LDT): • Developed and validated internally by a single CLIA-certified lab • No FDA pre-market review historically — "enforcement discretion" • FDA LDT Final Rule (2024): phased oversight, high-risk LDTs require 510(k)/PMA review